SCHEMBL30788883

SCHEMBL30788883

COC(=O)[C@H](CCSCCC(C)(C)C)NC(=O)OC(C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 7/20 0.45
CTSS P25774 5/20 0.45
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
HTT P42858 1/20 0.44
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
EPHX2 P34913 1/20 0.39
PPARG P37231 2/20 0.38
PPARA Q07869 2/20 0.38
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA7 P43166 1/20 0.37
GSTP1 P09211 1/20 0.37
GSTM2 P28161 1/20 0.37
KLK7 P49862 1/20 0.37
ALDH1A1 P00352 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30788752 0.87 CTSK (0.49) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL6354784 0.87 CTSK (0.46) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL24299005 0.87 CTSK (0.46) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL24335310 0.86 CYP1A2 (0.49) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL24335172 0.86 CYP1A2 (0.49) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL22381011 0.85 CTSK (0.51) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL30788856 0.85 CTSK (0.50) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL30788790 0.85 CTSK (0.45) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL25216116 0.84 CTSK (0.42) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL30788996 0.83 CTSS (0.54) CTSKCTSSCYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034094-A1 COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS KOJIN THERAPEUTICS INC (US) 2026-02-05 US disclosed
EP-4565228-A2 COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS Kojin Therapeutics, Inc. (US) 2025-06-11 EP disclosed
WO-2024030960-A2 COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS Kojin Therapeutics, Inc. (US) 2024-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034094-A1 COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS AIFM2, GPX4, HMOX1 CTSK 1113/4885CTSS 886/4885CYP1A2 4432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.